Marsh & McLennan stock upgraded by Wells Fargo with USD 235 target
Published on 11/19/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWells Fargo Turns More Positive
- Wells Fargo raised its Marsh & McLennan rating to Overweight and set a 235 US-dollar price target.
- The company enters the new analyst call after quarterly earnings exceeded consensus and revenue increased year over year.
On Thursday, November 19, 2026, Wells Fargo upgraded Marsh & McLennan from Equal Weight to Overweight and set a 235 US-dollar price target, according to MarketBeat. The move gives the insurance and professional-services group a more supportive analyst stance while keeping the focus on valuation and the outlook for its brokerage, consulting and risk businesses.
Marsh & McLennan stock traded at 187.40 euros on Lang & Schwarz at 13:38 CET on Thursday, November 19, 2026, 0.03 percent above the Xetra close of Wednesday, November 18, at 187.35 euros. The comparison uses the previous completed Xetra session because the European market was still open at the quoted time.
What Wells Fargo Changed
Wells Fargo moved its recommendation one step higher, from Equal Weight to Overweight. The bank's target places the shares above the broader analyst average cited by MarketBeat, which was 210.63 US dollars across the tracked recommendations. The report follows a series of recent research updates, including Morgan Stanley's move to 215 US dollars from 190 US dollars while retaining an Equal Weight rating.
The different recommendations point to a market still weighing Marsh & McLennan's durable fee-based businesses against a potentially softer insurance cycle. Marsh, Guy Carpenter, Mercer and Oliver Wyman give the group exposure to insurance brokerage, reinsurance services, health and wealth consulting, workforce advice and management consulting. That mix can support recurring client demand, but revenue growth and margins remain sensitive to corporate spending, insurance pricing and investment activity.
Why The Rating Matters
MarketBeat also cited Marsh & McLennan's latest quarterly performance. Earnings per share came in at 2.03 US dollars against a 1.96 US-dollar consensus estimate, while revenue rose 8.1 percent year over year to 6.86 billion US dollars. Those figures provide the operating backdrop for the new rating, although Wells Fargo's upgrade is an analyst judgment rather than a change to the company's own guidance.
The target revision therefore matters chiefly as a signal about expected relative performance. A higher rating can improve the market's view of the shares, but the company still faces the same cycle, execution and valuation questions that shape the wider insurance-services group. Investors will likely focus on organic growth, renewal pricing, consulting demand and the contribution from recent strategic investments.
Market Context And Next Steps
Marsh & McLennan reported its latest quarterly results on October 15, 2026, according to the MarketBeat account. The next material company-specific catalyst should be the group's next earnings release, when investors can compare operating growth with the expectations embedded in the new analyst target.
Marsh & McLennan Company Facts
- Company: Marsh & McLennan Companies, Inc.
- ISIN: US5717481023
- NYSE ticker: MRSH
- Primary exchange: NYSE
- Lang & Schwarz quote: 187.40 euros on November 19, 2026, at 13:38 CET
- Xetra close: 187.35 euros on November 18, 2026
- Market capitalization: 89.59 billion euros
- 52-week range: 133.95 to 191.15 euros
The S&P 500 provides the relevant US market backdrop for Marsh & McLennan.
More coverage is available in More news and analyses on Marsh & McLennan stock.
